Curated News
By: NewsRamp Editorial Staff
April 22, 2026
Nutriband CEO Discusses AVERSA™ Tech to Combat Opioid Crisis on Podcast
TLDR
- Nutriband's AVERSA technology offers a competitive edge by addressing the opioid crisis with a patented abuse-deterrent fentanyl patch, potentially capturing market share in pharmaceutical safety.
- AVERSA technology works by incorporating abuse-deterrent features into transdermal patches to prevent misuse, diversion, and accidental exposure of high-risk drugs while maintaining patient access.
- This technology makes the world better by reducing opioid abuse and accidental exposure, helping protect communities and improve patient safety in pain management.
- Nutriband's CEO discussed on a podcast how their transdermal patch technology can deter fentanyl abuse through innovative design backed by global patents.
Impact - Why it Matters
This news matters because the opioid crisis remains a severe public health emergency, with fentanyl and similar drugs contributing to thousands of overdoses and deaths annually. Nutriband's AVERSA™ technology represents a proactive approach to mitigating abuse and accidental exposure, which could enhance patient safety and reduce societal harm. By developing abuse-deterrent transdermal patches, the company addresses a critical gap in pain management, potentially influencing regulatory standards and healthcare practices. For investors and stakeholders, this innovation signals growth opportunities in the pharmaceutical sector, while for the general public, it offers hope for safer medication options that balance therapeutic access with risk reduction.
Summary
Nutriband Inc. (NASDAQ: NTRB), a company primarily engaged in transdermal pharmaceutical development, made headlines as its CEO and Co-Founder Gareth Sheridan appeared on the Jack Neel Podcast to address the ongoing opioid crisis. The core discussion centered on the company's innovative AVERSA™ abuse-deterrent transdermal technology, which is specifically designed to tackle critical issues like misuse, diversion, and accidental exposure of high-risk drugs such as fentanyl. This technology aims to maintain essential patient access to necessary medications while incorporating safety features that deter abuse, supported by a broad global patent portfolio that underscores its proprietary nature and potential market exclusivity.
The lead product under development is an abuse-deterrent fentanyl patch that integrates the AVERSA™ technology, highlighting Nutriband's focus on creating solutions for drugs with significant abuse potential. The company's website, www.nutriband.com, serves as a resource for further information, though it is noted that content from the site is not part of the official press release. This announcement was distributed through BioMedWire, a specialized communications platform within the Dynamic Brand Portfolio @ IBN, which enhances visibility via wire solutions, editorial syndication, and social media distribution to reach investors and the public effectively.
For those interested in deeper insights, the full press release is available at https://ibn.fm/fSUKj, and updates related to NTRB can be found in the company's newsroom at https://ibn.fm/NTRB. BioMedWire, powered by IBN, provides a robust platform for disseminating such news in the biotechnology and life sciences sectors, ensuring that key messages about innovative technologies like AVERSA™ reach a wide audience. This engagement underscores the importance of collaborative efforts in addressing public health challenges through technological advancements.
Source Statement
This curated news summary relied on content disributed by InvestorBrandNetwork (IBN). Read the original source here, Nutriband CEO Discusses AVERSA™ Tech to Combat Opioid Crisis on Podcast
